Moreover, the potential impact of genetic variants on the treatment of NASH can be encapsulated by the example of PNPLA3 I148M variant and the response to treatment (Sanyal et al., 2015; Wattacheril et al., 2018). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.